Elanco Animal Health Incorporated financials
$22.61+0.71%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.71B | $4.44B | $4.42B | $4.41B | $4.76B | $3.27B | $3.07B | $3.07B |
| Gross profit | $2.59B | $2.44B | $2.49B | $2.50B | $2.63B | $1.60B | $1.60B | $1.49B |
| Gross margin | 55.0% | 54.9% | 56.3% | 56.6% | 55.2% | 49.0% | 52.1% | 48.7% |
| Operating income | $15.0M | $101.0M | -$843.0M | $169.0M | -$330.0M | -$705.0M | $185.0M | $185.0M |
| Net income | -$232.0M | $338.0M | -$1.23B | -$78.0M | -$483.0M | -$574.0M | $68.0M | $86.5M |
| Net margin | −4.9% | 7.6% | −27.9% | −1.8% | −10.1% | −17.5% | 2.2% | 2.8% |
| Diluted EPS | $-0.47 | $0.68 | $-2.50 | $-0.16 | $-0.99 | $-1.30 | $0.18 | $0.28 |
| EBITDA | $932.0M | $913.0M | $1.02B | $1.03B | $1.02B | $435.0M | $685.0M | $609.8M |
| Operating cash flow | $560.0M | $541.0M | $271.0M | $452.0M | $483.0M | -$41.0M | $224.0M | $487.3M |
| Free cash flow | $284.0M | $394.0M | $131.0M | $281.0M | $324.0M | -$176.0M | $84.0M | $352.8M |
| Diluted shares | 496.4M | 497.3M | 492.3M | 488.3M | 487.2M | 441.4M | 370.3M | 313.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $545.0M | $468.0M | $352.0M | $345.0M | $638.0M | $495.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $4.02B | $4.32B | $5.77B | $5.84B | $6.32B | $6.13B |
| Total assets | $13.36B | $12.61B | $14.36B | $15.49B | $16.48B | $17.69B |
| Total liabilities | $6.81B | $6.52B | $8.14B | $8.20B | $8.97B | $9.22B |
| Shareholders' equity | $6.55B | $6.10B | $6.22B | $7.29B | $7.51B | $8.48B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology